Maciej Banach

Maciej Banach

POLAND

 

 

 

 

Dr. Maciej Banach was an Undersecretary of State at Ministry of Science and Higher Education of Republic of Poland (2010-2012). He is a President of Polish Mother’s Memorial Hospital – Research Institute (2014-), full Professor of Cardiology at Medical University of Lodz, Head of Foreign Affairs Office (2012-2014), Head of Department of Hypertension (2008-) at Medical University of Lodz, and Professor in the Department of Nephrology, Hypertension and Family Medicine, Chair of Nephrology and Hypertension, at WAM University Hospital in Lodz, Poland. He is a Founder and Head of Polish Lipid Association (PoLA) (2011-) – the official partner of National Lipid Association (NLA, US) and Lodz Chapter of Polish Society of Hypertension (2009-). He is a Visiting Professor of University of Alabama at Birmingham (UAB) and University of Medicine and Pharmacy Victor Babes in Timisoara, Romania (2014).
Dr. Banach has published more than 500 original articles, reviews, editorials, and book chapters in the field of hypertension, dyslipidemias, cardiology, cardiac surgery, and risk stratification (204 acc. to PubMed, 249 acc. to Web of Knowledge, 253 acc. to SCOPUS, and 449 acc. to Google Scholar). His combined IF (for only full-text manuscripts) is over 660 pts., number of citations: 2164 (acc. Web of Knowledge), 2529 (acc. SCOPUS), and 3607 (acc. Google Scholar), Hirsch’s Index = 24 (WoS), 25 (SCOPUS), and 30 (i10-index: 111) (Google Scholar).
He is Editor-in-Chief of the Archives of Medical Science journal (IF2013=1.890) and Cardiovascular Continuum, Deputy Editor of Thyroid Research and Clinical and Experimental Medical Letters (2007-2012), Associate/Section Editor of Recent Patents on Cardiovascular Drugs Discovery and The Open Atherosclerosis & Thrombosis Journal and member of Editorial Advisory Board of 27 international medical journals such as Journal of Hypertension, Angiology, Medical Science Monitor, International Journal of Pharmacology, International Journal of Hypertension, Biology of Sport, Expert Opinion on Pharmacotherapy, and Current Drug Therapy. He is Reviewer of over 70 international journals, including Lancet, Circulation, British Medical Journal, Journal of American College of Cardiology, European Heart Journal, Atherosclerosis, American Journal of Cardiology, and International Journal of Cardiology. He is editor or author of 26 books (89 chapters).
He is a fellow of the Council for High Blood Pressure Research of American Heart Association (FAHA), National Lipid Association (FNLA), American Society of Angiology (FASA), European Society of Cardiology (FESC), Royal Society for Public Health (FRSPH) and Society of Geriatric Cardiology (FSGC; 2008-2010). He is a founder of Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2012-), member of working-core of Alliance for Biomedical Research/European Council for Health Research (2011-2013), steering committee of European Innovation Partnership in Active and Healthy Ageing (2010-2012) at European Commission (Brussels), and steering committee of Centre for Good Aging / Healthy Ageing Research Center (HARC) at Medical University of Lodz, member of Committee for Public Health of Polish Academy of Sciences, member of the Scientific Board of Institute of Sport in Warsaw, Poland.
He is a laureate of many prizes and award, including: The Personality of the Year 2013 in Poland for the development of science in the field of healthcare – founded by the Heath Manager journal (Termedia Publishing House), Super-Talent in Medicine 2012 Award – the winner of the competition for young scientists in medicine (up to 40) founded by Puls Medycyny journal; scientific awards of Ministry of Health of Republic of Poland for the cycle of publications (2009, 2011), 11 individual and group scientific awards of President of Medical University of Lodz (2009-2013); START Award (2008) and Conferences Awards (2005, 2007) of Foundation for Polish Science, Polityka journal Awards for Young Scientists (2006), and Travel Grants of European Society of Hypertension (2007) and Heart Failure Association of ESC (2005, 2007).
His main area of scientific interests concerns hypertension aspects (risk stratification, prehypertension, new biomarkers, optimal level of BP – J-curve phenomenon, pharmacotherapy/combined therapy, prevention, complications), lipid disorders (risk stratification, new biomarkers, diagnosis, rare diseases), dyslipidemia therapy (statins, new drugs combined treatment), new drugs in CVD therapy.